Milestone shares fell 20.6% after earnings, as investors likely focused on the gap between launch growth and the company’s need to cut costs: CARDAMYST prescriptions rose 50% quarter over quarter, but Milestone is reducing operating expenses by about 30% and restructuring its commercial organization. The transcript does not provide a revised sales outlook; the cost measures and leadership departures suggest the launch has yet to support the prior operating structure.
Shares declined 15.7% following the quarter as investors reacted negatively to persistent low market access, with only 25% commercial insurance coverage during Q2 limiting growth potential despite early launch progress.
Shares fell 9.5% following the quarter as investors reacted negatively to cautious early sales performance and a lack of clear near-term revenue acceleration despite a successful product launch and broad coverage progress.